Compare NATL & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NATL | MYGN |
|---|---|---|
| Founded | 2023 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 444.2M |
| IPO Year | 2023 | 1996 |
| Metric | NATL | MYGN |
|---|---|---|
| Price | $44.42 | $4.77 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $45.60 | $7.64 |
| AVG Volume (30 Days) | 1.0M | ★ 1.5M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.98 | N/A |
| EPS | ★ 2.14 | N/A |
| Revenue | ★ $4,354,000,000.00 | $771,400,000.00 |
| Revenue This Year | $6.13 | $6.89 |
| Revenue Next Year | $4.24 | $5.35 |
| P/E Ratio | $20.32 | ★ N/A |
| Revenue Growth | 0.86 | ★ 2.33 |
| 52 Week Low | $23.18 | $3.76 |
| 52 Week High | $48.50 | $8.59 |
| Indicator | NATL | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 57.28 | 50.55 |
| Support Level | $35.92 | $4.23 |
| Resistance Level | $48.50 | $5.69 |
| Average True Range (ATR) | 0.87 | 0.26 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 90.61 | 70.25 |
NCR Atleos Corp is financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware and its proprietary Allpoint network. Atleos manage its operations in the following segments which includes Self-Service Banking, Network, and Telecommunications abd Technology.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.